Pharmacodynamic Effects of Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus: The Optimizing Anti-Platelet Therapy In Diabetes MellitUS (OPTIMUS)-5 Study

Next Previous
Trial Profile

Pharmacodynamic Effects of Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus: The Optimizing Anti-Platelet Therapy In Diabetes MellitUS (OPTIMUS)-5 Study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs Vorapaxar (Primary) ; Aspirin; Clopidogrel
  • Indications Diabetes mellitus; Myocardial infarction
  • Focus Pharmacodynamics
  • Acronyms OPTIMUS-5

    • Most Recent Events

    • 29 Mar 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
    • 29 Mar 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Sep 2018.
    • 15 Mar 2017 Planned End Date changed from 1 Oct 2017 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top